- Home
- NAAS vs SNTI Comparison
NAAS vs SNTI Comparison
Compare NAAS & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NAAS | SNTI |
|---|---|---|
| Founded | 2019 | 2016 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.5M | 24.5M |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | NAAS | SNTI |
|---|---|---|
| Price | $2.41 | $0.90 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 3.8K | ★ 105.9K |
| Earning Date | 03-31-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $378.49 | N/A |
| Revenue Next Year | N/A | $150.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.41 | $0.80 |
| 52 Week High | $4.54 | $5.10 |
Technical Indicators
Market Signals| Indicator | NAAS | SNTI |
|---|---|---|
| Relative Strength Index (RSI) | 52.56 | 41.61 |
| Support Level | $2.22 | $0.80 |
| Resistance Level | $3.77 | $1.02 |
| Average True Range (ATR) | 0.12 | 0.05 |
| MACD | 0.07 | -0.00 |
| Stochastic Oscillator | 72.86 | 20.64 |
Price Performance
Historical ComparisonAbout NAAS NaaS Technology Inc.
Naas Technology Inc is an electric vehicle charging service provider in China, whose vision is to power the world with carbon-neutral energy. It offers an integrated set of online solutions to charging station operators, a wide range of offline services that simplify the daily operations of charging station operators, and non-charging services such as food and beverage services to station operators.
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.